Global Biomarkers Market Insights Forecasts to 2033

• The Global Biomarkers Market Size was Valued at USD 80.02 Billion in 2023.
• The Market Size is Growing at a CAGR of 13.22% from 2023 to 2033.
• The Worldwide Biomarkers Market Size is Expected to Reach USD 277.01 Billion by 2033.
• Asia Pacific is expected to grow the fastest during the forecast period.

The Global Biomarkers Market Size is Anticipated to Exceed USD 277.01 Billion by 2033, Growing at a CAGR of 13.22% from 2023 to 2033.  

Market Overview

Quantitative indications of biological functions, diseases, or therapeutic outcomes were observed with the help of biomarkers. Biomarkers are commonly referred to be minimally or non-invasive technologies. These are coupled with critical imaging and data management technologies. These tools are commonly used in imaging technology to produce clear images of cancer tumors and other issues. Biomarkers decrease the risk of exposure to radiation during MRI and CT scans. These biomarkers mainly consist of proteins, DNA, RNA, metabolites, and other compounds. Biomarkers are used in a variety of medical research applications, including diagnosis, prognosis, and treatment monitoring. They are helpful in illness identification, progression evaluation, treatment effectiveness determination, and therapy response predictions. The increasing incidence of cancer, the importance of companion diagnostics, research investments, and major advances resulting from current research are expected to fuel market expansion. According to the National Institutes of Health on February 2023 announced that Eastern Virginia Medical School (EVMS) would receive USD 4 Billion in funding for biomarker research and development for early diagnosis of severe prostate cancer.

Report Coverage

This research report categorizes the market for the global biomarkers market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global biomarkers market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global biomarkers market.

Driving Factors

The increased number of chronic diseases, as well as technological improvements in the discovery of biomarkers and biomarker-based diagnostic procedures, such as biomarker signatures, are making neurological diseases more manageable. Furthermore, the growing number of infectious and uncommon genetic disease cases, as well as the aging population, will drive the use of such agents in the coming years. These agents are employed in diagnostics to determine the existence or threat of a specific disease, as well as in safety evaluations and drug discovery. The ongoing development of biotechnological tools and techniques, like as genomics, proteomics, and high-throughput screening, has transformed biomarker discovery and verification. This has resulted in the development of new biomarkers with broad specificity and sensitivity, hence improving diagnostic and prognostic capacities. Furthermore, the paradigm switch toward personalized medicine is primarily focused on biomarkers to customize treatments to specific patient profiles.

Restraining Factors

Biomarkers require significant investment and capital. This slows the development and research of diagnostic and personal drugs. Calibration of biomarkers is a lengthy process. This provides biomarker industries with low-cost advantages. In addition, the availability of low-cost alternatives to biomarkers hampers the expansion of the biomarker market.

Market Segmentation

The global biomarkers market share is classified into type, disease type, and application.

• The safety biomarkers segment is expected to grow at the fastest pace in the global biomarkers market during the forecast period.   

Based on type, the global biomarkers market is divided into safety biomarkers, efficacy biomarkers, and validation biomarkers. Among these, the safety biomarkers segment is expected to grow at the fastest pace in the global biomarkers market during the forecast period. Factors contributing to this segment's major share include rising public knowledge of routine health checks, reduced drug use rates, and a rise in the number of persons suffering from chronic conditions. Furthermore, the significant market share of safety biomarkers is due to their growing application in the drug discovery process. Additional factors, such as increased expenditure in R&D to develop novel diagnostic processes, are likely to drive up the use of safety biomarkers over the projection period.

• The cancer segment is expected to grow at the fastest pace in the global biomarkers market during the forecast period.

Based on the disease type, the global biomarkers market is divided into cardiovascular diseases, cancer, neurological diseases, and immunological diseases. Among these, the cancer segment is expected to grow at the fastest pace in the global biomarkers market during the forecast period. Tissue or cell cancer biomarkers must be evaluated using more aggressive methods than tissue biopsies or serum biomarkers. Cancer biomarkers can be discovered in tissues using specific methods, but they must be accessible as serum or urine biomarkers. DNA from tumor tissue, whole blood, or buccal mucosal cells can all be tested for genetic indicators. As a result, biomarkers are predicted to continue to play a significant role in both the identification and avoidance of cancer throughout all stages.

• The drug discovery & development segment is expected to hold the largest share of the global biomarkers market during the forecast period. 

Based on application, the global biomarkers market is divided into personalized medicine, diagnostics, drug discovery & development, and others. Among these, the drug discovery & development segment is expected to hold the largest share of the global biomarkers market during the forecast period. biomarkers are essential instruments in drug discovery and development, with a variety of crucial applications that optimize and enhance efficiency. Biomarkers facilitate the identification and validation of prospective therapeutic targets by giving information about their function in disease processes. This assures that drug development resources are directed toward biologically relevant targets. Biomarkers help to analyze the efficacy of medication candidates in preclinical and clinical trials.

Regional Segment Analysis of the Global Biomarkers Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global biomarkers market over the predicted timeframe.

North America is anticipated to hold the largest share of the global biomarkers market over the predicted timeframe. Global players have grown their R&D spending and local presence. Over the last period, the number of USFDA-approved medicine labels containing molecular biomarker data has risen substantially. In addition, practically all pharmaceutical corporations have produced molecular biomarker studies through collaborations or other initiatives. Molecular biomarkers are determined and validated throughout medication development before being used to support therapeutic approval. The authorization of such medications has aided the growth of the United States kidney biomarker market.

Asia Pacific is expected to grow at the fastest pace in the global biomarkers market during the forecast period. The growing rate of cancer and cardiovascular disease is boosting the demand for disease diagnostics, particularly biomarker-based assays. As a consequence, it boosts profit in this region. The use of biomarkers in the medication discovery and development process encourages important market participants to invest in research to generate novel biomarkers. These factors are expected to increase the need for biomarkers and drive market expansion.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global biomarkers along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc
• Merck KGaA
• PerkinElmer, Inc.
• Bio-Rad Laboratories, Inc.
• Enzo Biochem Inc.
• QIAGEN
• Agilent Technologies, Inc.
• Bruker
• Epigenomics AG
• MESO SCALE DIAGNOSTICS, LLC
• EKF Diagnostics Holdings plc
• General Electric Company
• Nexus- Dx
• LifeSign LLC
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In October 2023, Mindray revealed the introduction of high-sensitivity NT-proBNP and troponin I (hs-cTnI) cardiac biomarkers. The introduction will improve the company's range of cardiac biomarkers for managing and diagnosing cardiovascular diseases.

• In February 2023, Cardio Diagnostics Holdings Inc. introduced PrecisionCHD, an epigenetic-genetic blood test for detecting coronary heart disease in its early stages.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Global Biomarkers Market based on the below-mentioned segments:

Global Biomarkers Market, By Type

• Safety Biomarkers
• Efficacy Biomarkers
• Validation Biomarkers

Global Biomarkers Market, By Disease Type

• Cardiovascular Diseases
• Cancer
• Neurological Diseases
• Immunological Diseases

Global Biomarkers Market, By Application

• Personalized Medicine
• Diagnostics
• Drug Discovery & Development
• Others

Global Biomarkers Market, By Region

• North America
  • US
  • Canada
  • Mexico 
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa